
Group Leader Antiviral Activities of Antibodies @Virus_Immunity @institutpasteur - Virology/Immunology - Member @SFV_France - @timotheebruel.bsky.social
Paris
Joined May 2010
- Tweets3.2K
- Following958
- Followers1.9K
- Likes8.6K
Pinned Tweet
1/ 🧵Thrilled to share that our new paper was just published at @ScienceTM @aaas ! 🎉
We show how the complement system boosts the ability of antibodies to neutralize SARS-CoV-2, especially recent variants. 🦠🧫
science.org/doi/10.1126/scit…
A thread ⬇️
What an amazing opportunity !
Today, we’re announcing an open call for guest investigators in life sciences. Over 8–12 weeks, guest investigators will work directly with my team and other Anthropic researchers to produce analyses and tools for their work. We’ll run our models and harnesses, at no cost to them. We’ll work together to open-source the resulting data, artifacts, and code, and write preprints about what we find.
We want humans to remain at the center of scientific discovery, deciding what questions to pursue, and how to pursue them. Those decisions are not ours to make alone. This open call is part of our ongoing efforts at Anthropic to support researchers and accelerate scientific discovery.
I’m looking for principal investigators and their research groups at academic institutions, nonprofits, or government labs, working in causal human biology, structural and computational molecular biology, medicinal chemistry, drug discovery, and clinical science.
Applications are open for about 14 days: anthropic.com/news/open-call…
Timothée Bruel retweeted
Need compute to compete in protein design competitions like this one?
proteinbase.com/competitions…
RFD4-Proteina is now on Hugging Face with two weeks of NVIDIA-sponsored access. 🧵👇
China has selected its first group of young researchers to receive funding for up to 15 years, in one of the longest research grants on offer to scientists globally
go.nature.com/4z4Q3pw
Timothée Bruel retweeted
Here's the link: arxiv.org/pdf/2601.23265v1
If you want more practical ai gems and a list of full free ai resources, go here: simplifyingai.co/subscribe
Timothée Bruel retweeted
We are offering 10,000 scientists the highest usage tier in Google Antigravity free of charge for 6 months. Please apply! forms.gle/WvmBbPvRbpKG1BPn9
Timothée Bruel retweeted
Antiviral immunity via telomerase-like reverse transcription in bacteria nature.com/articles/s41586-0…
Timothée Bruel retweeted
Looks like an early flu season in the US.
Flu season is here and we're currently seeing a rise in flu emergency department visits, earlier than in previous seasons. Now is the time to get your flu shot! All New Yorkers 6 months and older should get an annual flu vaccine.
Learn more: nyc.gov/flu
Timothée Bruel retweeted
Large upload from Ontario yesterday, providing striking revelations about the evolution of PJ.2.1.
First, there is yet another hugely divergent branch of PJ.2.
This isn't one variant: it's four.
More & more, this resembles the emergence of BA.1/2/3. What is happening? 1/11
Timothée Bruel retweeted
L'épidémie de #grippe débute particulièrement tôt aux Etats-Unis (mais aussi au Royaume-Uni notamment) : ce pourrait être "une saison incroyablement précoce" et "il se trame quelque chose".
Le virus H1N1 est largement majoritaire, mais avec une nouvelle mutation, la G155E, qui inquiète les chercheurs.
En effet, "certaines souches porteuses de cette mutation sont, dans certains cas, moins bien reconnues par les anticorps humains préexistants", d'après un preprint.
A suivre !
nature.com/articles/d41586-0…
Nature research paper: Function-preserving watermarking of AI-generated proteins
go.nature.com/4hRb5S9
Timothée Bruel retweeted
This one is wild.
On an extended de novo protein binder design campaign:
Sonnet 5.5: 82.3%
Opus 5.5: 82.6%
Claude gets a protein target structure and up to 24 hours to design 30 miniprotein binders.
Sonnet is basically at Opus level here.
🤖 Made with AI
Timothée Bruel retweeted
"When the next pandemic happens, there may be something that comes out of the blue, and we’ll be lacking the knowledge we had for COVID. What we’re trying to do is stockpile some of that knowledge ahead of time.” - Joe Grove, @UofGlasgow
A new open dataset adds predicted protein-complex structures from more than 2,800 viruses to the AlphaFold Database.
📃 nvda.ws/47laLF2
Timothée Bruel retweeted
#WSV2027 – Keynote Speakers #2 🎤
1️⃣ Prof. Johan Neyts - @KULeuven, Belgium;
2️⃣ Dr. Indrani Karunasagar -Director (R&D), Nitte University, India
3️⃣ Dr. Olivier Schwartz - Institut Pasteur
4️⃣ Dr. Jürgen Richt - Kansas State University
#Virology #WSV2027
youtube.com/watch?v=vCXU5YEP…
Timothée Bruel retweeted
Claude has discovered a previously unknown enzyme system hidden in the DNA of bacteriophages. Beside the enzyme’s gene sits a long array of repeating DNA—a structure that looks somewhat similar to CRISPR.
We don’t yet understand what this system does, but only a handful of known systems share its features, and all of them are able to cut, copy, and paste DNA. Historically, the discovery of such programmable systems has helped revolutionize medicine. CRISPR, for instance, is now the foundation of genetic medicines. But it will take much more work to learn what this system does, and whether it can be put to similar use.
Read more: anthropic.com/news/claude-di…
Timothée Bruel retweeted
One of nine PJ.2.1 sequences uploaded from NYC today has A475V, which escapes some major class 1 antibodies. One of 2 two mAbs tested by @yunlong_cao that most potently neutralized PJ.2.1 (IC50=0.001) & to which it was much more vulnerable then XFG, is ~entirely escaped by A475V.
SARS-CoV-2 saltation variant PJ.2.1 has raised concerns over another JN.1-like event.
Here we found:
1. PJ.2.1 shows markedly higher ACE2 binding.
2. PJ.2.1's antigenicity remains comparable to the JN.1 family.
3. No increased immune evasion against human plasma.
While PJ.2.1 currently lacks the immune evasion capabilities of other contemporary strains (XFG, PQ.16.1.1, BA.3.2.2...), its robust baseline receptor-binding strength mirrors the early evolutionary trajectory of BA.2.86 to JN.1, necessitating continued genomic, epidemiological, and virological surveillance of the PJ.2.1 lineage.
Details can be found in the recent BioRxiv manuscript:
biorxiv.org/content/10.64898…
Timothée Bruel retweeted
SARS-CoV-2 saltation variant PJ.2.1 has raised concerns over another JN.1-like event.
Here we found:
1. PJ.2.1 shows markedly higher ACE2 binding.
2. PJ.2.1's antigenicity remains comparable to the JN.1 family.
3. No increased immune evasion against human plasma.
While PJ.2.1 currently lacks the immune evasion capabilities of other contemporary strains (XFG, PQ.16.1.1, BA.3.2.2...), its robust baseline receptor-binding strength mirrors the early evolutionary trajectory of BA.2.86 to JN.1, necessitating continued genomic, epidemiological, and virological surveillance of the PJ.2.1 lineage.
Details can be found in the recent BioRxiv manuscript:
biorxiv.org/content/10.64898…

























